Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P16298
UPID:
PP2BB_HUMAN
Alternative names:
CAM-PRP catalytic subunit; Calmodulin-dependent calcineurin A subunit beta isoform
Alternative UPACC:
P16298; P16299; Q5F2F9; Q8N1F0; Q8N3W4
Background:
The Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform, also known as CAM-PRP catalytic subunit and Calmodulin-dependent calcineurin A subunit beta isoform, is pivotal in intracellular Ca(2+)-mediated signal transduction. It dephosphorylates TFEB, facilitating lysosomal biogenesis, activates NFATC1, inactivates ELK1, and dephosphorylates DARPP32. Additionally, it plays a crucial role in skeletal muscle fiber type specification and negatively regulates MAP3K14/NIK signaling, impacting nuclear translocation of RELA and RELB.
Therapeutic significance:
Understanding the role of Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform could open doors to potential therapeutic strategies.